Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors

DISCUSSION: Eculizumab potentially offers a mechanism-based treatment of MG in patients under anti-programmed cell death protein 1 (PD-1) agents, without interfering with their mechanism of action and avoiding their discontinuation. Larger case series deserve to be evaluated.PMID:38108913 | DOI:10.1007/s10072-023-07190-0

Source: Cancer Control - December 18, 2023 Category: Cancer & Oncology Authors: Laura Fionda Elena Rossini Antonio Lauletta Luca Leonardi Laura Tufano Rocco Costanzo Paolo Marchetti Marco Salvetti Matteo Garibaldi Stefania Morino Giovanni Antonini Source Type: research